Valproic acid as anti-cancer drug

被引：87
|
作者：
Michaelis, Martin [1 ]
Doerr, Hans Wilhelm [1 ]
Cinatl, Jindrich, Jr. [1 ]
机构：
[1] Goethe Univ Frankfurt, Inst Med Virol, Zentrum Hyg, D-6000 Frankfurt, Germany
来源：
CURRENT PHARMACEUTICAL DESIGN | 2007年 / 13卷 / 33期
关键词：
valproic acid; HDAC; differentiation; angiogenesis; combination therapy; clinical studies; HISTONE DEACETYLASE INHIBITORS; TRANS-RETINOIC ACID; ACUTE MYELOID-LEUKEMIA; ACTIVATED-RECEPTOR-GAMMA; PROSTATE-SPECIFIC ANTIGEN; ACUTE MYELOGENOUS LEUKEMIA; FETAL HEMOGLOBIN-SYNTHESIS; APOPTOSIS-INDUCING LIGAND; PML NUCLEAR-BODIES; CANCER CELL-GROWTH;
D O I：
10.2174/138161207782360519
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The short chain fatty acid valproic acid (VPA, 2-propylpetanoic acid) is approved for the treatment of epilepsia, bipolar disorders and migraine and clinically used for schizophrenia. In 1999, the first clinical anti-cancer trial using VPA was initiated. Currently, VPA is examined in numerous clinical trials for different leukaemias and solid tumour entities. In addition to clinical assessment, the experimental examination of VPA as anti-cancer drug is ongoing and many questions remain unanswered. Although other mechanisms may also contribute to VPA-induced anti-cancer effects, inhibition of histone deacetylases appears to play a central role. This review focuses on recent developments regarding the anti-cancer activity of VPA.
引用
收藏
页码：3378 / 3393
页数：16
相关论文
共 50 条
  • [41] DNA anti-cancer drug design - Editorial
    Jing, NJ
    CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (22) : 2809 - 2809
  • [42] GPCRs: Emerging anti-cancer drug targets
    Gutierrez, Ainhoa Nieto
    McDonald, Patricia H.
    CELLULAR SIGNALLING, 2017, 41 : 65 - 74
  • [43] PROTIDES AS A NEW ANTI-CANCER DRUG FAMILY
    McGuigan, Christopher
    Serpi, Michaela
    Slusarczyk, Magdalena
    Ferrari, Valentina
    Jimenez-Antunez, Carmen
    ANTICANCER RESEARCH, 2015, 35 (07) : 4312 - 4312
  • [44] Correlation of anti-cancer drug structure to efficacy
    Turner, John
    Chalk, Stuart
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [45] Synthetic developments of anti-cancer drug genistien
    Cai, X.
    Yao, Z.-F.
    Yan, W.
    Liu, H.
    Jishou Daxue Xuebao/Journal of Jishou University, 2001, 22 (02): : 71 - 74
  • [46] The risk of anti-cancer related cardiotoxicities in colorectal cancer patients following different anti-cancer drug treatments
    Wen, Pin-Chun
    Ciou, Wan-Jyun
    Ho, Chin-Chin
    Yang, Chen-Chang
    CLINICAL TOXICOLOGY, 2020, 58 (04) : 337 - 338
  • [47] DRUG TO DRUG INTERACTIONS FROM THE NEWER ANTI-CANCER DRUGS
    Gennari, Alessandra
    BREAST, 2021, 59 : S34 - S34
  • [48] Topological Properties of Curcumin and Hyaluronic Acid Conjugated Molecular Structure: An Anti-Cancer Drug
    Rauf, Abdul
    Akram, Bushra
    Ishtiaq, Muhammad
    Siddiqui, Muhammad Kamran
    POLYCYCLIC AROMATIC COMPOUNDS, 2023, 43 (01) : 219 - 232
  • [49] Combination of multifunctional ursolic acid with kinase inhibitors for anti-cancer drug carrier vesicles
    Lorincz, A.
    Mihaly, J.
    Wacha, A.
    Nemeth, Cs.
    Besztercei, B.
    Gyulavari, P.
    Varga, Z.
    Petak, I.
    Bota, A.
    MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS, 2021, 131
  • [50] The risk of anti-cancer drugs related cardiotoxicities in colorectal cancer patients following different anti-cancer drug treatments
    Wen, Pin-Chun
    Ciou, Wan-Jyun
    Ho, Chin-Chin
    Yang, Chen-Chang
    CLINICAL TOXICOLOGY, 2019, 57 (12) : 1182 - 1183
12345